With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday.

SaveHealth explores the historical trajectory of weight loss drugs, examining their scientific basis, regulatory battles, public reception, and what lies ahead for pharmacotherapy in obesity ...